IL1B and histiocytic sarcoma: Likewise, elevated serum and lesional skin levels of TNF- α, IL1β, IL-10, and IL-17 in the HS subjects than healthy individuals propose these inflammatory markers as potential therapeutic targets as they affect different phases of HS pathology [18].